Treatment Approaches

Prognosis remains poor in MCL, and patients who respond to treatment usually relapse. There is currently no standard treatment for the disease. Conventional treatment of MCL results in response rates of 20-60%. The disease invariably recurs and the median survival in this disease is approximately 3 years. Therapeutic options are continually being refined as the clinical methods of classifying MCL evolve and as the biology elucidates the histologic and cytogenetic characteristics of MCL subtypes.

0 0

Post a comment